Hematology, transfusion and cell therapy · 2026
Clinical characteristics, prognosis, and achievement of transplant in adolescents and adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in Argentina.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Clavijo María Manuela, Ruiz Juan Ignacio, Ferrari Luciana, Conca Alberto Gimenez, Delorenzi Agostina, Rapan Leticia, Cazap Nicolas, Rivas María Marta, Moya Eliana, Agamennoni Lucía, Vega Celina Guadalupe, Freue Julian, Funes Maria Eugenia, Dick Hernan Daniel, Mullen Mercedes Mac, Navickas Alicia, Fernandez Isolda, Carnelutto Natalia, Vicente Claudia, Moirano María, Basquiera Ana Lisa, Belli Carolina
Аннотация
INTRODUCTION: Data on clinical outcomes and allogeneic stem cell transplantation for Latin American Philadelphia chromosome-negative acute lymphoblastic leukemia patients are limited. This study aimed to characterize this population and identify factors influencing overall survival among adolescents and adults with this malignancy in Argentina. Additionally, the study examined the predictors of proceeding to first-line allogeneic stem cell transplantation in this population.
METHODS: This retrospective cohort study included patients diagnosed at 15 centers between 2014 and 2022. Descriptive, univariate, and multivariate analyses were conducted.
RESULTS: Three hundred and five patients with a median age of 34 years were included. Median overall survival was 42 months. Treatment at public healthcare institutions (hazard ratio: 1.61), central nervous system involvement (hazard ratio: 1.56), high-risk status defined by the receipt of Berlin-Frankfurt-Münster-like or hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) regimens (hazard ratio: 1.89), and older age (hazard ratio: 1.02) were independently associated with a worse outcome. In a subgroup analysis of 199 patients with an indication and eligibility to receive allogeneic stem cell transplantation, 20.1% underwent the procedure. Receiving treatment at public institutions was associated with a 65% lower likelihood of undergoing transplantation (p-value = 0.013), an effect that remained consistent when death or relapse was accounted for as a competing event (Subdistribution Hazard Ratio: 0.28).
CONCLUSIONS: In this acute lymphoblastic leukemia Argentinean cohort, overall survival was influenced by classical predictors of a worse outcome and by healthcare disparities. Receiving treatment at public institutions adversely diminished access to first-line allogeneic stem cell transplantation, which may account for the poorer outcome.
METHODS: This retrospective cohort study included patients diagnosed at 15 centers between 2014 and 2022. Descriptive, univariate, and multivariate analyses were conducted.
RESULTS: Three hundred and five patients with a median age of 34 years were included. Median overall survival was 42 months. Treatment at public healthcare institutions (hazard ratio: 1.61), central nervous system involvement (hazard ratio: 1.56), high-risk status defined by the receipt of Berlin-Frankfurt-Münster-like or hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) regimens (hazard ratio: 1.89), and older age (hazard ratio: 1.02) were independently associated with a worse outcome. In a subgroup analysis of 199 patients with an indication and eligibility to receive allogeneic stem cell transplantation, 20.1% underwent the procedure. Receiving treatment at public institutions was associated with a 65% lower likelihood of undergoing transplantation (p-value = 0.013), an effect that remained consistent when death or relapse was accounted for as a competing event (Subdistribution Hazard Ratio: 0.28).
CONCLUSIONS: In this acute lymphoblastic leukemia Argentinean cohort, overall survival was influenced by classical predictors of a worse outcome and by healthcare disparities. Receiving treatment at public institutions adversely diminished access to first-line allogeneic stem cell transplantation, which may account for the poorer outcome.